
A new study identifies lysine-specific demethylase 1 (LSD1) as a key driver in the progression of preneoplastic lesions to oral squamous cell carcinoma (OSCC). Inhibiting LSD1 reverses preneoplasia, disrupts immunosuppression, and suppresses STAT3 signaling, highlighting LSD1 as a promising therapeutic target.
Like
Save
Share